References
- Eleutherakis-Papaiakovou V, Bamias A, Gika D, Simeonidis A, Pouli A, Anagnostopoulos A, et al. Renal failure in multiple myeloma: incidence, correlations, and prognostic significance. Leuk Lymphoma 2007; 48: 337–341
- Augustson B M, Begum G, Dunn J A, Barth N J, Davies F, Morgan G, et al. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002 – Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 2005; 23: 9219–9226
- Clark W F, Stewart A K, Rock G A, Sternbach M, Sutton D M, Barrett B J, et al. Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial. Ann Intern Med 2005; 143: 777–784
- Carlson K, Hjorth M, Knudsen L M. Toxicity in standard melphalan-prednisone therapy among myeloma patients with renal failure – a retrospective analysis and recommendations for dose adjustment. Br J Haematol 2005; 128: 631–635
- Vigneau C, Ardiet C, Bret M, Laville M, Fiere D, Tranchand B, et al. Intermediate-dose (25 mg/m2) IV melphalan for multiple myeloma with renal failure. J Nephrol 2002; 15: 684–689
- Knudsen L M, Nielsen B, Gimsing P, Geisler C. Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failure. Eur J Haematol 2005; 75: 27–33
- Tosi P, Zamagni E, Cellini C, Cangini D, Tacchetti P, Tura S, et al. Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure. Eur J Haematol 2004; 73: 98–103
- Rajkumar S V, Hayman S, Gertz M A, Dispenzieri A, Lacy M Q, Greipp P R, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002; 20: 4319–4323
- Jagannath S, Barlogie B, Berenson J R, Singhal S, Alexanian R, Srkalovic G, et al. Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function. Cancer 2005; 103: 1195–1200